Immunwork is developing new class of immunoterapies using its own technology platforms to develop drugs carrying both targeting (T) and effector (E) functions to increase efficacy and safety of many existing drugs.
Immunwork was founded by Dr. Tse Wen Chang, with immense industry and research experience in antibody design and development. Dr. Chang conceived the concept of T-E drug design platform.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
Immuwork technology platform enables the design of a class of new drugs, term as _T-ETM pharmaceuticalsÓ with both targeting (T) and effector (E) moieties and technology can be used to prepare ADCs, bispecific and multi-specific antibodies, which have improved product homogeneity, drug payloads, target-binding valency, and consistency in the manufacturing process.
Recover your password.
A password will be e-mailed to you.